Increased expression of the prolactin receptor is associated with malignant laryngeal tumors

González-Lucano,Luis  R.; Muñoz-Valle,José  F.; Ascencio-Cedillo,Rafael; Domínguez-Rosales,José  A.; López-Rincón,Gonzalo; Del Toro-Arreola,Susana; Bueno‑Topete,Miriam; Daneri-Navarro,Adrián; Estrada-Chávez,Ciro; Pereira-Suárez,Ana  L.

doi:10.3892/etm.2012.464

Increased expression of the prolactin receptor is associated with malignant laryngeal tumors

Authors:
- Luis R. González-Lucano
- José F. Muñoz-Valle
- Rafael Ascencio-Cedillo
- José A. Domínguez-Rosales
- Gonzalo López-Rincón
- Susana Del Toro-Arreola
- Miriam Bueno‑Topete
- Adrián Daneri-Navarro
- Ciro Estrada-Chávez
- Ana L. Pereira-Suárez
View Affiliations

Affiliations: Department of Physiology, University Center for Health Sciences, University of Guadalajara, Guadalajara, Jalisco, Mexico, Department of Molecular Biology and Genomics, University Center for Health Sciences, University of Guadalajara, Guadalajara, Jalisco, Mexico, Institute of Chronic Degenerative Diseases, University Center for Health Sciences, University of Guadalajara, Guadalajara, Jalisco, Mexico, Unit of Medical and Pharmaceutical Biotechnology, Center for Research and Assistance in Technology and Design of Jalisco, Guadalajara, Jalisco, Mexico
Published online on: January 30, 2012 https://doi.org/10.3892/etm.2012.464
Pages: 603-607

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The altered expression of the prolactin receptor (PRLR) has been associated with the development of various types of cancer, particularly breast, prostate and endometrial cancer. However, in laryngeal tumors, the expression of PRLR has not yet been documented. The aim of this study was to determine the expression and localization of PRLR in laryngeal cancer (LC) in comparison with recurrent respiratory papillomatosis (RRP). PRLR expression was analyzed in 48 paraffin‑embedded tissues (18 RRP and 30 laryngeal cancer tissues) by immunoperoxidase staining. Furthermore, PRLR expression was evaluated in ten samples from each group by Western blot analysis and quantitative real-time PCR. PRLR was observed in all laryngeal tumors at different intensities. PRLR overexpression was significantly associated (P<0.005) with LC. The staining pattern was homogeneous, mainly cytoplasmic, and confined to the tumor area. We found increased expression of different isoforms in LC in comparison with RRP. Our results suggest a possible role of PRL/PRLR in the development of LC. PRLR may be useful as a target for further investigations in laryngeal tissues.

View Figures

View References

1.	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
2.	Derkay CS: Recurrent respiratory papillomatosis. Laryngoscope. 111:57–69. 2001. View Article : Google Scholar
3.	Penaloza-Plascencia M, Montoya-Fuentes H, Flores-Martinez SE, Fierro-Velasco FJ, Penaloza-Gonzalez JM and Sanchez-Corona J: Molecular identification of 7 human papillomavirus types in recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg. 126:1119–1123. 2000. View Article : Google Scholar
4.	Hashibe M, Boffetta P, Zaridze D, et al: Contribution of tobacco and alcohol to the high rates of squamous cell carcinoma of the supraglottis and glottis in Central Europe. Am J Epidemiol. 165:814–820. 2007. View Article : Google Scholar : PubMed/NCBI
5.	Cordes C, Munzel AK, Rudolph P, Hoffmann M, Leuschner I and Gottschlich S: Immunohistochemical staining of Ki-67 using the monoclonal antibody Ki-s11 is a prognostic indicator for laryngeal squamous cell carcinoma. Anticancer Res. 29:1459–1465. 2009.PubMed/NCBI
6.	McHale K, Tomaszewski JE, Puthiyaveettil R, Livolsi VA and Clevenger CV: Altered expression of prolactin receptor-associated signaling proteins in human breast carcinoma. Mod Pathol. 21:565–571. 2008. View Article : Google Scholar : PubMed/NCBI
7.	Leav I, Merk FB, Lee KF, et al: Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. Am J Pathol. 154:863–870. 1999. View Article : Google Scholar
8.	Levina VV, Nolen B, Su Y, et al: Biological significance of prolactin in gynecologic cancers. Cancer Res. 69:5226–5233. 2009. View Article : Google Scholar : PubMed/NCBI
9.	Rui H, Kirken RA and Farrar WL: Activation of receptor-associated tyrosine kinase JAK2 by prolactin. J Biol Chem. 269:5364–5368. 1994.PubMed/NCBI
10.	Al-Sakkaf KA, Dobson PR and Brown BL: Prolactin induced tyrosine phosphorylation of p59fyn may mediate phosphatidylinositol 3-kinase activation in Nb2 cells. J Mol Endocrinol. 19:347–350. 1997. View Article : Google Scholar : PubMed/NCBI
11.	Das R and Vonderhaar BK: Activation of raf-1, MEK, and MAP kinase in prolactin responsive mammary cells. Breast Cancer Res Treat. 40:141–149. 1996. View Article : Google Scholar : PubMed/NCBI
12.	Nohara A, Ohmichi M, Koike K, et al: Prolactin stimulates mitogen-activated protein kinase in human leiomyoma cells. Biochem Biophys Res Commun. 238:473–477. 1997. View Article : Google Scholar : PubMed/NCBI
13.	Ben-Jonathan N, Lapensee CR and Lapensee EW: What can we learn from rodents about prolactin in humans? Endocr Rev. 29:1–41. 2008. View Article : Google Scholar : PubMed/NCBI
14.	Peirce SK and Chen WY: Quantification of prolactin receptor mRNA in multiple human tissues and cancer cell lines by real time RT-PCR. J Endocrinol. 171:R1–R4. 2001. View Article : Google Scholar : PubMed/NCBI
15.	Yuan JS, Reed A, Chen F and Stewart CN Jr: Statistical analysis of real-time PCR data. BMC Bioinformatics. 7:852006. View Article : Google Scholar : PubMed/NCBI
16.	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17.	Tworoger SS and Hankinson SE: Prolactin and breast cancer risk. Cancer Lett. 243:160–169. 2006. View Article : Google Scholar : PubMed/NCBI
18.	Stattin P, Rinaldi S, Stenman UH, et al: Plasma prolactin and prostate cancer risk: A prospective study. Int J Cancer. 92:463–465. 2001. View Article : Google Scholar : PubMed/NCBI
19.	Meyer F, Samson E, Douville P, Duchesne T, Liu G and Bairati I: Serum prognostic markers in head and neck cancer. Clin Cancer Res. 16:1008–1015. 2010. View Article : Google Scholar : PubMed/NCBI
20.	Yurkovetsky Z, Ta’asan S, Skates S, et al: Development of multi-marker panel for early detection of endometrial cancer. High diagnostic power of prolactin. Gynecol Oncol. 107:58–65. 2007. View Article : Google Scholar : PubMed/NCBI
21.	Harbaum L, Pollheimer MJ, Bauernhofer T, et al: Clinicopathological significance of prolactin receptor expression in colorectal carcinoma and corresponding metastases. Mod Pathol. 23:961–971. 2010. View Article : Google Scholar
22.	Bauernhofer T, Pichler M, Wieckowski E, et al: Prolactin receptor is a negative prognostic factor in patients with squamous cell carcinoma of the head and neck. Br J Cancer. 104:1641–1648. 2011. View Article : Google Scholar : PubMed/NCBI
23.	Gill S, Peston D, Vonderhaar BK and Shousha S: Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study. J Clin Pathol. 54:956–960. 2001. View Article : Google Scholar : PubMed/NCBI
24.	Brockman JL, Schroeder MD and Schuler LA: PRL activates the cyclin D1 promoter via the Jak2/Stat pathway. Mol Endocrinol. 16:774–784. 2002. View Article : Google Scholar : PubMed/NCBI
25.	Varghese B, Barriere H, Carbone CJ, et al: Polyubiquitination of prolactin receptor stimulates its internalization, postinternalization sorting, and degradation via the lysosomal pathway. Mol Cell Biol. 28:5275–5287. 2008. View Article : Google Scholar
26.	Plotnikov A, Li Y, Tran TH, et al: Oncogene-mediated inhibition of glycogen synthase kinase 3 beta impairs degradation of prolactin receptor. Cancer Res. 68:1354–1361. 2008. View Article : Google Scholar : PubMed/NCBI
27.	Li Y, Clevenger CV, Minkovsky N, et al: Stabilization of prolactin receptor in breast cancer cells. Oncogene. 25:1896–1902. 2006. View Article : Google Scholar : PubMed/NCBI
28.	Binart N, Bachelot A and Bouilly J: Impact of prolactin receptor isoforms on reproduction. Trends Endocrinol Metab. 21:362–368. 2010. View Article : Google Scholar : PubMed/NCBI
29.	Ginsburg E, Alexander S, Lieber S, et al: Characterization of ductal and lobular breast carcinomas using novel prolactin receptor isoform specific antibodies. BMC Cancer. 10:6782010. View Article : Google Scholar